ABIO vs. ACHV, TKNO, VNRX, ICCC, OCX, TRIB, AWH, CDIO, BMRA, and MYMD
Should you be buying ARCA biopharma stock or one of its competitors? The main competitors of ARCA biopharma include Achieve Life Sciences (ACHV), Alpha Teknova (TKNO), VolitionRx (VNRX), ImmuCell (ICCC), OncoCyte (OCX), Trinity Biotech (TRIB), Aspira Women's Health (AWH), Cardio Diagnostics (CDIO), Biomerica (BMRA), and MyMD Pharmaceuticals (MYMD). These companies are all part of the "diagnostic substances" industry.
Achieve Life Sciences (NASDAQ:ACHV) and ARCA biopharma (NASDAQ:ABIO) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, earnings, risk, profitability, institutional ownership, dividends, valuation and community ranking.
Achieve Life Sciences currently has a consensus price target of $14.00, suggesting a potential upside of 184.26%. Given ARCA biopharma's higher probable upside, equities analysts clearly believe Achieve Life Sciences is more favorable than ARCA biopharma.
Achieve Life Sciences has a beta of 1.54, suggesting that its stock price is 54% more volatile than the S&P 500. Comparatively, ARCA biopharma has a beta of 0.9, suggesting that its stock price is 10% less volatile than the S&P 500.
33.5% of Achieve Life Sciences shares are held by institutional investors. Comparatively, 56.4% of ARCA biopharma shares are held by institutional investors. 2.0% of Achieve Life Sciences shares are held by company insiders. Comparatively, 30.9% of ARCA biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
ARCA biopharma is trading at a lower price-to-earnings ratio than Achieve Life Sciences, indicating that it is currently the more affordable of the two stocks.
Achieve Life Sciences received 207 more outperform votes than ARCA biopharma when rated by MarketBeat users. Likewise, 70.21% of users gave Achieve Life Sciences an outperform vote while only 41.84% of users gave ARCA biopharma an outperform vote.
Achieve Life Sciences' return on equity of -16.08% beat ARCA biopharma's return on equity.
In the previous week, Achieve Life Sciences had 1 more articles in the media than ARCA biopharma. MarketBeat recorded 5 mentions for Achieve Life Sciences and 4 mentions for ARCA biopharma. Achieve Life Sciences' average media sentiment score of 0.38 beat ARCA biopharma's score of 0.06 indicating that ARCA biopharma is being referred to more favorably in the news media.
Summary
Achieve Life Sciences and ARCA biopharma tied by winning 7 of the 14 factors compared between the two stocks.
Get ARCA biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for ABIO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ABIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ARCA biopharma Competitors List
Related Companies and Tools
Free ABIO Stock Alerts